Ruben Mesa

  • 19584 Citations
  • 66 h-Index
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Ruben Mesa is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Primary Myelofibrosis Medicine & Life Sciences
Polycythemia Vera Medicine & Life Sciences
Essential Thrombocythemia Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Myeloproliferative Disorders Medicine & Life Sciences
Janus Kinase 2 Medicine & Life Sciences
Splenomegaly Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1997 2019

1 Citation (Scopus)

A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis

Mascarenhas, J., Kosiorek, H., Prchal, J., Yacoub, A., Berenzon, D., Baer, M. R., Ritchie, E., Silver, R. T., Kessler, C., Winton, E., Finazzi, M. C., Rambaldi, A., Vannucchi, A. M., Leibowitz, D., Rondelli, D., Arcasoy, M. O., Catchatourian, R., Vadakara, J., Rosti, V., Hexner, E. & 12 others, Kremyanskaya, M., Sandy, L., Tripodi, J., Najfeld, V., Farnoud, N., Salama, M. E., Weinberg, R. S., Rampal, R., Goldberg, J. D., Mesa, R., Dueck, A. C. & Hoffman, R., Jan 1 2019, (Accepted/In press) In : Leukemia.

Research output: Contribution to journalLetter

Essential Thrombocythemia
Polycythemia Vera

Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis

Palmer, J., Kosiorek, H. E., Wolschke, C., Fauble, V. D. S., Butterfield, R., Geyer, H., Scherber, R. M., Dueck, A. C., Gathany, A., Mesa, R. A. & Kroger, N., Nov 2019, In : Biology of Blood and Marrow Transplantation. 25, 11, p. 2267-2273 7 p.

Research output: Contribution to journalArticle

Primary Myelofibrosis
Stem Cells
Quality of Life
Stem Cell Transplantation

Corrigendum to “Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib” [Leukemia Res. 79 (2019) 38–44] (Leukemia Research (2019) 79 (38–44), (S0145212619300384), (10.1016/j.leukres.2019.02.012))

Gerds, A. T., Tauchi, T., Ritchie, E., Deininger, M., Jamieson, C., Mesa, R., Heaney, M., Komatsu, N., Minami, H., Su, Y., Shaik, N., Zhang, X., DiRienzo, C., Zeremski, M., Chan, G. & Talpaz, M., Jan 1 2019, In : Leukemia Research.

Research output: Contribution to journalComment/debate

Primary Myelofibrosis

Developing a model to predict accrual to cancer clinical trials: Data from an NCI designated cancer center

Iruku, P., Goros, M., Gelfond, J., Chang, J., Padalecki, S., Mesa, R. & Kaklamani, V. G., Sep 1 2019, In : Contemporary Clinical Trials Communications. 15, 100421.

Research output: Contribution to journalArticle

Open Access
Clinical Trials
Financial Management
Area Under Curve

Development of a symptom assessment in patients with myelofibrosis: Qualitative study findings

Mesa, R. A., Su, Y., Woolfson, A., Prchal, J. T., Turnbull, K., Jabbour, E., Scherber, R., Shields, A. L., Krohe, M., Ojo, F., Pompilus, F., Cappelleri, J. C. & Harrison, C., Apr 11 2019, In : Health and Quality of Life Outcomes. 17, 1, 61.

Research output: Contribution to journalArticle

Open Access
Primary Myelofibrosis
Symptom Assessment


MATCH REPORT: FC Barcelona v RC Recreativo: Reserves smiling again (3-1)

Ruben Mesa


1 item of Media coverage

Press/Media: Press / Media

Lista de convocados ante el Cádiz C.F.

Ruben Mesa


1 item of Media coverage

Press/Media: Press / Media